WELCOME TO THE PEPTIDE BASED THERAPEUTICS SUMMIT
Designing, Synthesising & Identifying the Optimal Peptide Based Drugs
Positioned in the goldilocks spot between small molecules and biologics, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies, together with novel design and delivery strategies to surmount their inherent drawbacks, this modality is showing new levels of promise. The momentum behind this exciting modality is evidenced in the billion-dollar deals from industry giants such as Genentech and Merck, signalling a surge in interest from an expanding array of companies venturing into the field of next-generation peptide-based drugs.
The first industry-focused event dedicated towards this exciting new modality, the Peptide Based Therapeutics Summit will unite pioneers from Johnson & Johnson, Fog Pharma, Genentech & PeptiDream, spanning diverse diseases and therapeutic approaches. Whether you're focused on peptide-drug conjugates, bicyclic or macro-cyclic peptides, PCSK9, GLP, or any other peptide based therapeutic, this is an invaluable opportunity to learn from peers, accelerate discovery and de-risk the development of your peptide therapeutics.
As we enter the third wave of peptide-based therapeutics, this therapeutic and disease agnostic meeting will bring together the leading minds in early discovery, pre-formulation, heads of peptide drug development and pioneering peptide chemists. Together, we will dissect challenges related to improving peptide stability, raising oral bioavailability and balancing cell permeability with intracellular target selectivity, as well as exploring how the latest cutting-edge technology can help you arrive at the optimal lead compound. Join this meeting to help shape the trajectory of these remarkable drugs across various therapeutic landscapes.
WORLD-CLASS SPEAKER FACULTY INCLUDES:
Professor - Chemistry
PeptiDream & University of Tokyo
Senior Principal Scientist
Executive Vice President - Discovery Biology
WHAT OUR ATTENDEES ARE LOOKING FORWARD TO:
“Very excited to continue to share learnings with colleagues about how peptides can be turned into therapeutics across a diverse array of indications and applications”
Pete Gough, Chief Scientific Officer, Nimble Therapeutics